The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for ...

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.